Skip to main content

Table 1 Patient characteristics at baseline according to treatment arm

From: A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises

 

Treatment with WBV

Treatment without WBV

p value

N = 66

N = 65

Sex, male/female

29/37

34/31

0.38

Age, years, median (Range)

59 (28–70)

62 (24–71)

0.10

Diagnosis, no. (%)

  

0.85

 Hematological malignancies

23 (35)

21(32)

 

  Multiple myeloma

8 (12)

11 (17)

 

  Lymphomas

10 (15)

7 (11)

 

  Leukemias

5 (7.5)

3 (5)

 

 Solid tumors

43 (65)

44 (68)

 

  Colorectal

13 (20)

12 (18.5)

 

  Lung

5 (7.5)

3 (4.5)

 

  Esophageal/gastric

2 (3)

10 (15)

 

  Breast/ovarian

13 (20)

12 (18.5)

 

  Other

7 (10.5)

4 (6)

 

Disease state (excl. leukemias)

 Multiple myeloma (Salmon-Durie)

  I

 

3

 

  II

4

1

 

  III

4

7

 

 Lymphoma (Ann-Arbor)

  I

1

  

  II

1

  

  III

4

1

 

  IV

4

6

 

 Solid tumors (WHO)

  I

2

4

 

  II

8

10

 

  III

19

10

 

  IV

14

20

 

Pretreatment, no. (%)

 Radiotherapy

28 (42%)

18 (28%)

0.10

 Chemotherapy

66 (100%)

65 (100%)

 

 Combination chemotherapya

64 (97%)

63 (97%)

0.99

 Platinum-based

27 (41%)

35 (54%)

0.16

 Taxane-based

22 (33%)

17 (26%)

0.45

 Vinca alkaloids

9 (14%)

8 (12%)

0.99

 Bortezomib

6 (9%)

7 (11%)

0.78

Time since last chemotherapy

 In months, median (range)

2 (0–98)

0 (0–51)

0.07

Time since first chemotherapy

  In months, median (range)

19 (4–156)

9 (2–180)

0.005

Treatment related neuropathy

 NCI-CTC

  Grade II

28 (42%)

35 (54%)

0.22

  Grade III

38 (58%)

30 (46%)

 

  Active treatment to control pain, No. (%)

15 (23%)

21 (32)

0.24

  Chemotherapy during study No. (%)

25 (38%)

34 (51%)

0.12

  1. WBV whole-body vibration therapy, WHO World Health Organization, NCI CTC National Cancer Institute Common Toxicity Criteria
  2. aSingle agent chemotherapy; experimental arm, n = 2, arsenic trioxide, radioiodine therapy; standard arm, n = 2, cladribine, trastuzumab